• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers use gold nanoparticles to deliver hepatitis C vaccine

December 20, 2016 By Sarah Faulkner

Researchers use gold nanoparticles to deliver hepatitis C vaccineResearchers at Brigham & Women’s Hospital have developed electrically activated gold nanoparticles that can bore holes into cells’ outer membranes and allow DNA, RNA and proteins to pass through carrying their cargo. The team’s work was published in Advanced Functional Materials.

The team tested its technique using a DNA vaccine against hepatitis C in a mice model. Over the course of 3 months, the researchers did not observe any signs of toxicity. The newly developed delivery method induced high levels of anti-hepatitis C virus antibodies and immune cells that secreted inflammatory hormones.

“Our concept is unique,” first author Mohamed Shehata Draz said in prepared remarks. “Both the electric field parameters and the nanoparticle properties can be augmented to perform other important functions, such as precisely removing cells or blood clots.”

DNA vaccines, which have also shown promise as a method for slowing cancer growth, are a potential alternative to conventional vaccines. DNA vaccines are not constructed with weakened microbes, like standard vaccines.

“One of the really exciting aspects of this new method is that it enables drug delivery into tissues or cells in a universal way,” lead researcher Hadi Shafiee explained. “We are eager to explore its use for other important biological molecules, including RNA.”

Filed Under: Featured, Immunotherapy, Nanoparticles, Research & Development Tagged With: Brigham & Women's Hospital

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS